How to address second and therapy‐related acute myelogenous leukaemia
C Oliai, G Schiller - British Journal of Haematology, 2020 - Wiley Online Library
Secondary acute myelogenous leukaemia (AML), as compared to de novo AML, occurs in the
more elderly population, is independently more resistant to cytotoxic chemotherapy, has a …
more elderly population, is independently more resistant to cytotoxic chemotherapy, has a …
[HTML][HTML] Stereotactic body radiation therapy for the primary treatment of localized prostate cancer
C Oliai, R Lanciano, B Sprandio, J Yang… - Journal of radiation …, 2013 - Springer
Objective The low alpha/beta ratio of prostate cancer suggests that hypofractionated schemes
of dose-escalated radiotherapy should be advantageous. We report our experience using …
of dose-escalated radiotherapy should be advantageous. We report our experience using …
Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis
C Oliai, B Fisher, A Jani, M Wong, J Poli… - International Journal of …, 2012 - Elsevier
PURPOSE: To provide a retrospective analysis of the efficacy of hyperbaric oxygen therapy (HBOT)
for treating hemorrhagic cystitis (HC) and proctitis secondary to pelvic- and prostate-…
for treating hemorrhagic cystitis (HC) and proctitis secondary to pelvic- and prostate-…
Allogeneic hematopoietic stem cell transplantation for older patients with acute myeloid leukemia
R Levin-Epstein, C Oliai, G Schiller - Current treatment options in oncology, 2018 - Springer
Opinion statement Acute myelogenous leukemia (AML) in the elderly is complex and has a
poor prognosis, often characterized by higher risk cytogenetic and molecular features …
poor prognosis, often characterized by higher risk cytogenetic and molecular features …
[HTML][HTML] Case report: sustained remission achieved from anti-CD19 CAR T cell therapy despite prior treatment with anti-CD19 antibody tafasitamab (MOR208) in a …
C Oliai, S de Vos - Blood, 2019 - Elsevier
Introduction: Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody
that targets CD19. L-MIND (NCT02399085) is an ongoing, open-label, single-arm, phase II …
that targets CD19. L-MIND (NCT02399085) is an ongoing, open-label, single-arm, phase II …
[HTML][HTML] Patient characteristics and outcomes of outpatient tisagenlecleucel recipients for B cell non-Hodgkin lymphoma
…, LJ Nastoupil, OO Oluwole, VG Patel, C Oliai… - … and Cellular Therapy, 2023 - Elsevier
Tisagenlecleucel (tisa-cel) is an approved CD19-directed chimeric antigen receptor T cell (CAR-T)
therapy for relapsed/refractory B cell malignancies. Given potentially life-threatening …
therapy for relapsed/refractory B cell malignancies. Given potentially life-threatening …
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions
…, TJ Voorhees, S Carlson, D Gaut, C Oliai… - Blood …, 2023 - ashpublications.org
Checkpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after …
mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after …
CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma
…, K Nawaly, M Mead, S de Vos, PA Young, C Oliai… - Cancer discovery, 2023 - AACR
Autologous CD19/CD20 bispecific CAR-T cell therapy generated from T N/MEM cells for
patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and …
patients with NHL is safe (no neurotoxicity, maximum grade 1 cytokine release syndrome) and …
Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ T cell responses during the effector phase in vivo
…, AC Boesteanu, YM Mueller, CH Oliai… - The Journal of …, 2011 - journals.aai.org
Although much is known about the initiation of immune responses, much less is known about
what controls the effector phase. CD8+ T cell responses are believed to be programmed in …
what controls the effector phase. CD8+ T cell responses are believed to be programmed in …
Clinical features of pseudocirrhosis in metastatic breast cancer
C Oliai, ML Douek, C Rhoane, A Bhutada… - Breast cancer research …, 2019 - Springer
Purpose Pseudocirrhosis has been demonstrated to mimic cirrhosis radiographically, but
studies evaluating the pathophysiology and clinical features are lacking. To better understand …
studies evaluating the pathophysiology and clinical features are lacking. To better understand …